Biophytis Stock: price and insider trades · France
No insider purchase over the last 90 days. The latest, by STANISLAS VEILLET, was filed 04 Mar 2024.
Biophytis: what insiders have been doing
Biophytis is a Healthcare & Pharma company. Its directors and officers file their transactions with AMF. Biophytis has had no insider filing for more than a year; the last one goes back to 5 March 2024.
Our records for Biophytis go back to 2021, with 2 purchases and 6 sales on the open market in total.
In the same sector, recent insider purchases at Dynavox Group AB and EssilorLuxottica also feature in our signals. Every figure here comes from the filings published by AMF and describes the past, not future prices; it is not investment advice.
Financial data
· cache
- 2,955,701 shares@ €0.0613.9% of flowOption d'achatEuronext Growth ParisISIN FR00135072902024DD953457
- 1,680,000 shares@ €0.27Option d'achatEuronext Growth ParisISIN FR00128168252024DD953457-T2
- 313,417 shares0Option d'achatEuronext Growth ParisISIN FR00128168252024DD953438
- 586,583 shares@ €0.27Option d'achatEuronext Growth ParisISIN FR00128168252024DD953438-T2
- 500,000 shares@ €0.99839.1% of flowActionEuronext Growth ParisISIN FR00128168252024DD953409
- 400,000 shares@ €0.921519.7% of flowActionEuronext Growth ParisISIN FR00128168252024DD953409-T2
- 8,443,190 shares@ €0.00946.2% of flowActionEuronext Growth ParisISIN FR00128168252024DD953337Canonical exit: 20 Feb 2024 (T+90)
- 8,443,190 shares0Option d'achatEuronext Growth ParisISIN FR001400LN792024DD953337-T2Canonical exit: 20 Feb 2024 (T+90)
- 606,618 shares@ €0.27BSAEuronext Growth ParisISIN FR00128168252021DD759762-T3
- 440,000 shares@ €0.91226.8% of flowActionEuronext Growth ParisISIN FR00128168252021DD759762-T2
- 569,271 shares@ €0.91440.8% of flowActionEuronext Growth ParisISIN FR00128168252021DD759762
- 50,424 shares@ €0.403327.8% of flowPLAN BSPCE BIOPHYTIS 22/12/2010 ET 03/04/2020Euronext Growth ParisISIN FR00128168252021DD746589
- 50,424 shares@ €1.0572.2% of flowActionEuronext Growth ParisISIN FR00128168252021DD746591
- 67,627 shares@ €0.44100.0% of flowBSAEuronext Growth ParisISIN FR00128168252021DD736768
14 of 14 declarations
About Biophytis
Biophytis SA is a French biotechnology company focused on developing innovative therapies for age-related diseases, with a core mission of preserving mobility, muscle function, and patient independence. Founded in 2006, the company emerged from an academic research project centered on the biology of aging and has since built a scientific platform dedicated to healthy longevity. Biophytis is headquartered in France and operates through an international footprint that includes clinical, regulatory, and partnership activities across Europe, the United States, Brazil, and Asia.
Its business model is centered on BIO101, also known as 20-hydroxyecdysone, a small-molecule drug candidate being developed for multiple indications. The most advanced program targets sarcopenia, an age-related loss of muscle mass and strength in older adults, where Biophytis aims to establish BIO101 as a differentiated therapeutic option in a still underserved market. The company is also developing BIO101 in obesity, specifically addressing the muscle-wasting complications associated with obesity, which broadens the clinical and commercial opportunity for the asset. In parallel, Biophytis has launched a longevity research platform, enhanced by artificial intelligence, to identify new therapeutic candidates and expand beyond BIO101.
Read moreShow less
Biophytis is best described as a clinical-stage biotech, meaning its valuation and strategic progress depend heavily on trial execution, regulatory milestones, and access to financing. The company does not yet have a marketed product and therefore remains exposed to the inherent risks of drug development, including clinical uncertainty, regulatory delays, and capital needs. In 2025 and 2026, Biophytis reported a number of strategic steps, including regulatory progress in sarcopenia and obesity, as well as financing and development partnerships in Asia and Latin America. These initiatives underline the company’s ambition to build an international growth platform around longevity and muscle-health therapeutics.
Notable features of Biophytis include its strong positioning within the longevity theme, its narrow focus on frailty and muscle-loss disorders, and its partnership-led strategy to accelerate both research and future commercialization. As such, Biophytis stands out among French biotech companies for its specialization in the biology of aging and related therapeutic opportunities.
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
